Drug Trial Radar · NCT02735070
Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold
Last checked: Nov 20, 2026Latest source record: Apr 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
366
Planned (sponsor's estimate)
Start
Sep 2016
Primary completion
Mar 2017
Study completion Mar 2017
Sponsor
- Lead sponsor
- Brainfarma Industria Química e Farmacêutica S/AIndustry
- Sponsor type
- Industry
- Collaborators
- Techtrials Pesquisa e Tecnologia Ltda; Pharmagenix
- First posted
- Apr 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the non-inferiority of Coristina® d in the symptomatic treatment of the common cold compared to Resfenol® comparator.
Conditions
- Cold
Interventions
ResfenolDrug
Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Coristina dDrug
Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global Evaluation from 1 to 3 days after last doseTime frame: From 1 to 3 days after the last dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.